Φορτώνει......
Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4
BACKGROUND: The Oxaliplatin plus 5-Fluorouracil /Leucovorin (FOLFOX4) regimen have been approved by Chinese Food and Drug Administration (CFDA), and covered by health insurance for patients with advanced hepatocellular carcinoma (HCC) in China. However, the efficacy of FOLFOX4 for HCC patients is st...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Asian Pac J Cancer Prev |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
West Asia Organization for Cancer Prevention
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5555527/ https://ncbi.nlm.nih.gov/pubmed/28610406 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/APJCP.2017.18.5.1225 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|